Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Bicycle Therapeutics (BCYC) over the last 7 years, with Q3 2025 value amounting to $69.3 million.

  • Bicycle Therapeutics' Shares Outstanding (Diluted Average) rose 45.64% to $69.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.3 million, marking a year-over-year increase of 45.64%. This contributed to the annual value of $58.2 million for FY2024, which is 6353.96% up from last year.
  • According to the latest figures from Q3 2025, Bicycle Therapeutics' Shares Outstanding (Diluted Average) is $69.3 million, which was up 45.64% from $69.3 million recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' Shares Outstanding (Diluted Average) peaked at $69.3 million during Q3 2025, and registered a low of $22.1 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $41.0 million, with a median of $30.2 million in 2023.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 7431.79% in 2024, then soared by 45.64% in 2025.
  • Over the past 5 years, Bicycle Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $25.1 million in 2021, then grew by 18.35% to $29.7 million in 2022, then rose by 20.0% to $35.6 million in 2023, then surged by 63.54% to $58.2 million in 2024, then rose by 19.06% to $69.3 million in 2025.
  • Its last three reported values are $69.3 million in Q3 2025, $69.3 million for Q2 2025, and $69.2 million during Q1 2025.